NIAID/NIH recognizes the potency of UB-421 against multi-drug resistant HIV and receives the FDA approval to conduct a phase 2 clinical trial with UB-421 ...Middle East

TAIPEI, Aug. 31, 2022 /PRNewswire/ -- United BioPharma (UBP) announced today that the U.S. Food and Drug Administration (FDA) has approved a phase 2 clinical trial IND submitted by the U.S. National Institute of Allergy and Infectious Diseases (NIAID) of NIH. The purpose of this study is...

Hence then, the article about niaid nih recognizes the potency of ub 421 against multi drug resistant hiv and receives the fda approval to conduct a phase 2 clinical trial with ub 421 was published today ( Wednesday 31/08/2022 - 07:28 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( NIAID/NIH recognizes the potency of UB-421 against multi-drug resistant HIV and receives the FDA approval to conduct a phase 2 clinical trial with UB-421 )

Also on site :

• The Supreme Court Cast Its Lot With Trumpism. It Should Be Very Worried.
• UN renews Sudan ceasefire appeal over ‘unimaginable suffering’ of civilians
• Central African Republic election: Who’s running and what’s at stake?